Document is current
Any future updates will be listed below
-
Authors
Whitehead, Michael
Harvey, Joshua P.
Sladen, Paul E.
Becchi, Giada
Singh, Kritarth
Sun, Yujiao Jennifer
Burgoyne, Thomas
Duchen, Michael R.
Yu-Wai-Man, Patrick
Cheetham, Michael E.
-
Funding
Funding for this research was provided by:
NIHR Biomedical Research Centre
Moorfields Eye Charity
NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology (NIHR203322, NIHR203322, NIHR203322, NIHR203322)
Fight for Sight UK (5167/5168, 5167/5168)
MRC Career Development Award (MR/X020827/1)
NIHR Advanced Fellowship (NIHR301696)
NIHR Cambridge Biomedical Research Centre (NIHR203312)
Wellcome Trust Investigator Award (205041)
Macular Society (23-RG-01)
Foundation Fighting Blindness (PPA-0123-0841-UCL)
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 31 January 2025
First Online: 13 February 2025
Declarations
:
: For the use of patient-derived fibroblasts in this study, informed consent was obtained following the tenets of the Declaration of Helsinki. Ethical approval was granted by the Yorkshire and The Humber-Leeds Bradford Research Ethics Committee (REC reference: 13/YH/0310).
: Not applicable.
: PYWM is a consultant for GenSight Biologics, Stoke Therapeutics, PYC Therapeutics and has received research support from GenSight Biologics and Chiesi. MEC is a consultant for Prime Medicine.
